Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 14/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22673208 | 0.95 | SLC22A2 (0.63) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673212 | 0.88 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82019 | 0.85 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673051 | 0.85 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673195 | 0.85 | SLC22A2 (0.60) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21696394 | 0.85 | SLC22A2 (0.62) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19313012 | 0.85 | SLC22A2 (0.68) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673049 | 0.85 | SLC22A2 (0.60) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673197 | 0.84 | SLC22A2 (0.65) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17005315 | 0.84 | SLC22A2 (0.62) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365207-B2 | Sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV | MO, Yunfen (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20200361960-A1 | SULFUR-CONTAINING POLYCYCLIC-HYDROXYPYRIDONE CARBOXAMIDE ANALOG AGAINST HIV | MO, Yunfen | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365207-B2 | Sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV | TBK1, TYMP, TST | SLC22A2 1939/4885CYP3A4 1250/4885TMEM97 2615/4885 |
| US-20200361960-A1 | SULFUR-CONTAINING POLYCYCLIC-HYDROXYPYRIDONE CARBOXAMIDE ANALOG AGAINST HIV | TYMP, MAVS, DHPS | SLC22A2 1486/4885CYP3A4 1260/4885TMEM97 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.